Please like

FDA puts Gilead's Lenacapavir studies in HIV on hold due to vial quality concerns

Gilead Sciences(NASDAQ:GILD)announces that the FDA has placed a clinical hold on the use of injectab
FDA puts Gilead's Lenacapavir studies in HIV on hold due to vial quality concerns

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论3

  • 推荐
  • 最新
empty
暂无评论